Article
After two rounds of mixed data, Eli Lilly impresses analysts with new Covid-19 antibody results. An
Rating:
0.0
Views:
151
Likes:
1
Library:
1
Eli Lilly has more data from their Covid-19 neutralizing antibodies — data, they say, should warrant an FDA OK. The Big Pharma said Wednesday that a cocktail of two monoclonal antibodies looked safe and reduced viral load in Covid-19 patients. It also alleviated symptoms and reduced ER visits and hospitalization
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value